Dutch Study on CSF and PET Biomarker Concordance

The Dutch CSF and PET Biomarker Concordance of Alzheimer¡¡Âs Disease pathology study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON28575

Enrollment

Registered

2013-11-21

Start date

2013-11-20

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy controls, Alzheimer's Disease (AD) patients

Interventions

A Lumbar puncture is performed per local standard procedures and one Flutemetamol PET scan will be performed within 6 months.

Eligibility

Inclusion criteria

Inclusion criteria: Subjects - 50 to 85 years of age - Seen at the memory clinic of the VUmc Alzheimer Center for standardized dementia screening - who have signed informed consent form

Exclusion criteria

Exclusion criteria: Subjects who - are medically unstable -require additional laboratory tests or workup - receiving any investigational medications

Design outcomes

Primary

Measure	Time frame
To assess the concordance of [18F]Flutemetamol PET amyloid status across a range of detergent-based CSF tau:AƒÒ1-42 ratio assay values	—

Secondary

Measure	Time frame
To compare the concordance between [18F]Flutemetamol PET and the detergent-based CSF assay and the well established abeta 1-42, tau and p-tau assays used routinely in VUmc in the same range of patients	—

Contacts

Public ContactPh. Scheltens

VU Medisch Centrum De Boelelaan 1117

P.Scheltens@vumc.nl+31 (0)20 444 0715

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)